

## Biosyngen launches production base for immune cell therapeutics in China

04 January 2022 | News

**The facility is expected to boost further collaboration between China and Singapore**

The inauguration ceremony of Biosyngen joint projects and Biosyngen biological production base was held recently in China-Singapore Guangzhou Knowledge City (CSGKC).

As the largest production base for immune cells in Southern China, the facility covers an area of more than 10,000 square meters. With its phase 1 investment amounting to 200 million RMB, the facility will be designed, built and managed in strict accordance with GMP standards and customized to create fully-automated, fully-enclosed cellular drug production lines that ramps up commercialization of advanced technologies in biomedical field.

The facility is on track to enable Biosyngen develop safe, effective, and affordable cell therapies benefiting patients worldwide. Moreover, the facility is expected to boost further collaboration between China and Singapore in biotechnology, ultimately making an important contribution to the development of immunotherapy and clinical research of new technologies.

Biosyngen Chairman of the board, Zhang Qiong said that the production base will be an important vector for development and manufacturing of multiple pipelines of tumor-based CAR-T/TCR-T cell therapies in China.